|
|
|
13 November 2020
Phil Kerpen, President of American Commitment, discusses Commitment to Seniors, his organization's new project to shed light on public policies that harm seniors, how imposing foreign price controls on medicines will have devastating impacts on seniors and innovation, and the regulatory fights that may lie ahead.
0:00
0:00
Related Podcasts
28 August 2026
Phil Kerpen, Founder and President of American Commitment, discusses the Inflation Reduction Act’s drug price controls, how they hurt access and innovation, and why they must be repealed and replaced with pro-growth policies and strong intellectual property protections to encourage investment in new life-saving medicines.
04 April 2025
Sally Pipes, President and CEO of Pacific Research Institute, discusses her recently released book, “The World’s Medicine Chest: How America Achieved Pharmaceutical Supremacy and How to Keep It,” the horrible impacts of price controls, how single-payer healthcare systems fail children and cancer patients, and more.
02 September 2024
Sally Pipes, Founder and President of Pacific Research Institute, discusses the impact of drug price controls under the Inflation Reduction Act (IRA), what it means for research and development of life-saving medicines, and how the IRA's drug pricing provisions will reduce access to new cures and treatments and result in longer wait times for existing medicines.
28 June 2024
Sally Pipes, President and CEO of Pacific Research Institute, discusses how President Biden's price controls will result in prescription drug shortages and discourage innovation, how government mandates and regulations raise insurance costs, and the grim prognosis on Medicare and Medicaid's viability.
01 March 2024
Sally Pipes, President and CEO at the Pacific Research Institute, discusses how President Biden's drug price controls undermine his Cancer Moonshot initiative, and the ultimate impact price controls will have on patient lives, innovation, and research and development.
03 December 2021
Phil Kerpen, Founder and President of American Commitment, discusses how drug price controls would hurt seniors as they would reduce access to and undermine research and development in life-saving biopharmaceuticals, and why the Build Back Better Act under consideration in Congress is riddled with other disastrous provisions.
